# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001144204-15-054071
Filing Date
2015-09-09
Accepted
2015-09-08 17:47:04
Documents
25
Period of Report
2015-09-09
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM 8-K | v419724_8k.htm | 8-K | 14523
2 | EXHIBIT 99.1 | v419724_ex99-1.htm | EX-99.1 | 29403
3 | GRAPHIC | ex99x1_001.jpg | GRAPHIC | 76981
4 | GRAPHIC | ex99x1_002.jpg | GRAPHIC | 121301
5 | GRAPHIC | ex99x1_003.jpg | GRAPHIC | 104485
6 | GRAPHIC | ex99x1_004.jpg | GRAPHIC | 85439
7 | GRAPHIC | ex99x1_005.jpg | GRAPHIC | 78177
8 | GRAPHIC | ex99x1_006.jpg | GRAPHIC | 88887
9 | GRAPHIC | ex99x1_007.jpg | GRAPHIC | 95485
10 | GRAPHIC | ex99x1_008.jpg | GRAPHIC | 91525
11 | GRAPHIC | ex99x1_009.jpg | GRAPHIC | 111641
12 | GRAPHIC | ex99x1_010.jpg | GRAPHIC | 105635
13 | GRAPHIC | ex99x1_011.jpg | GRAPHIC | 96198
14 | GRAPHIC | ex99x1_012.jpg | GRAPHIC | 85976
15 | GRAPHIC | ex99x1_013.jpg | GRAPHIC | 88784
16 | GRAPHIC | ex99x1_014.jpg | GRAPHIC | 87503
17 | GRAPHIC | ex99x1_015.jpg | GRAPHIC | 106269
18 | GRAPHIC | ex99x1_016.jpg | GRAPHIC | 75335
19 | GRAPHIC | ex99x1_017.jpg | GRAPHIC | 112092
20 | GRAPHIC | ex99x1_018.jpg | GRAPHIC | 79818
21 | GRAPHIC | ex99x1_019.jpg | GRAPHIC | 81627
22 | GRAPHIC | ex99x1_020.jpg | GRAPHIC | 101203
23 | GRAPHIC | ex99x1_021.jpg | GRAPHIC | 108523
24 | GRAPHIC | ex99x1_022.jpg | GRAPHIC | 108116
25 | GRAPHIC | ex99x1_023.jpg | GRAPHIC | 76133
| Complete submission text file | 0001144204-15-054071.txt |  | 3032891

Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 4152444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-27436 | Film No.: 151097633
SIC: 2836 Biological Products, (No Diagnostic Substances)